JPH0456660B2 - - Google Patents
Info
- Publication number
- JPH0456660B2 JPH0456660B2 JP59132729A JP13272984A JPH0456660B2 JP H0456660 B2 JPH0456660 B2 JP H0456660B2 JP 59132729 A JP59132729 A JP 59132729A JP 13272984 A JP13272984 A JP 13272984A JP H0456660 B2 JPH0456660 B2 JP H0456660B2
- Authority
- JP
- Japan
- Prior art keywords
- droplets
- fluid
- capsule body
- solution
- functional substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002775 capsule Substances 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 31
- 239000012530 fluid Substances 0.000 claims description 29
- 150000004676 glycans Chemical class 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- 229920002101 Chitin Polymers 0.000 claims description 16
- 108010025899 gelatin film Proteins 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 229920001661 Chitosan Polymers 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229920000447 polyanionic polymer Polymers 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 carboxylmethyl Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000850 deacetylating effect Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZUQUTHURQVDNKF-KEWYIRBNSA-N 1-[(3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound CC(=O)C1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N ZUQUTHURQVDNKF-KEWYIRBNSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Description
産業上の利用分野
本発明は、不安定な機能性物質を内包したカプ
セル体およびその製造法、更に詳しくはポリアニ
オン多糖類又はその塩と可溶性キチン誘導体との
接触により形成されるゲル皮膜を利用した上記カ
プセル体およびその製造法に関する。
従来技術
従来、カプセル体の製造法として、カプセル体
の芯部を構成する流動体(芯液)にカルシウム塩
のような多価金属塩を添加した混合物を、アルギ
ン酸塩又は低メトキシルペクチンもしくはそれら
の混合物の溶液と接触させることによりゲル皮膜
を形成させる方法(特公昭48−16183号)、カルボ
キシルメチルキチンもしくはカルボキシルメチル
キチン塩の脱N−アセチル化物を含む水溶液を、
無水酢酸と酢酸の混合液のような有機酸の無水物
水溶液中に滴下、撹拌、分散させることによりカ
プセル体を製造する方法(特開昭55−90503号)
等が知られている。
しかし、これらの公知方法では不安定な機能性
物質、例えば有用物質を産生する動物細胞をカプ
セル化するに当つて次のような欠点を有する。
カプセル体の芯部を構成する液(芯液)のイ
オン強度が高すぎる。カプセルの形成過程で芯
液の水素イオン濃度の急激な変化がみられる。
芯液に含まれるカプセル膜形成に関与する物質と
不安定な機能性物質とが直接相互作用してその機
能性が消滅あるいは阻害されるおそれがある。
カプセル内液の粘度が高いのでカプセル内の物質
の均一な拡散が困難である。
発明が解決しようとする問題点
本発明者は、従来公知の方法で製造されるカプ
セル体における上述したような問題点に鑑み、特
に不安定な機能性物質に適したカプセル体につい
て検討した結果、キトサンのようなキチン誘導体
の溶液とポリアニオン多糖類又はその塩の溶液を
接触させると、生物学的に温和な条件下でも優れ
たゲル皮膜を形成すること、およびこの場合カプ
セル体に内包すべき不安定な機能性物質を含有す
る溶液の小滴を上記ポリアニオン多糖類又はその
塩の溶液で被覆したものを、上記キチン誘導体の
溶液と接触させてカプセル化すると、上記機能性
物質とカプセル形成に関与する物質との間の相互
作用が極めて弱くなると共にカプセル内の芯液の
粘度も非常に低くなることの知見を得て本発明を
なすに至つた。したがつて、本発明の目的は、特
に、不安定な機能性物質を、該物質の機能特性を
損なうことなくカプセル化し得るカプセル体およ
びその製造法を提供することにある。
以下本発明を詳しく説明する。
発明の構成
本発明に係るカプセル体の特徴は、不安定な機
能性物質を含有する流動体の小滴をポリアニオン
多糖類又はその塩もしくはそれらの混合物を主材
とする流動体で被覆した被覆小滴と可溶性キチン
誘導体の溶液との接触により形成されたゲル皮膜
で、上記被覆小滴を芯部として内包したことにあ
る。
また、本発明に係るカプセル体の製造法の特徴
は、不安定な機能性物質を含有する流動体を2重
円筒体ノズルの内筒ノズルから押出して小滴に形
成すると共に、該小滴の形成過程において、ポリ
アニオン多糖類又はその塩もしくはそれらの混合
物を主材とする流動体を上記内筒ノズルの外側に
平行的に配設された外筒ノズルから押出すことに
より、該流動体で上記形成される小滴を被覆し、
ついで得られた被覆小滴を可溶性キチン誘導体の
溶液と接触させてゲル皮膜を形成することにあ
る。
本発明において用いるポリアニオン多糖類又は
その塩は、水溶液中でポリアニオン重合体となる
多糖類またはその塩であつて、低メトキシルペク
チン、カラギナン、カルボキシメチルセルロー
ス、アルギン酸ナトリウム、コンドロイチン硫
酸、ヘパリン等を例示し得る。これらの多糖類は
単独又は混合物として用い得る。
また、本発明で用いる可溶性キチン誘導体は、
本来不溶性な物質であるキチンに化学的処理を施
してその反応活性を高めたものであつて、キチン
を脱アセチル化処理して得られるキトサンが代表
的なものとして例示し得る。
因に、キチンはカニ、オキアミ、昆虫などの甲
皮、微生物の細胞壁、きのこ類などに含まれるN
−アセチル−D−グルコサミンがβ(1→4)結
合した直鎖ホモ多糖体であつて、天然に豊富に生
産されているものであるが、その不活性の故にそ
のままでは利用できない未利用天然資源といえ
る。ところがキチンを脱アセチル化処理して得ら
れるキトサンのようなキチン誘導体は希酸に可溶
となり、反応活性を有するようになる。
すなわち、キトサンは下記一般式()で表わ
される構造単位を有し、
式中のアミノ基により正に帯電し、ポリカチオ
ン重合体としてキトサン分子を有していて反応活
性を示す。
問題点を解決するための手段
本発明においては、不安定な機能性物質を含有
する流動体を小滴に形成し、その形成過程で上記
ポリアニオン多糖類又はその塩もしくはそれらの
混合物を主材とする流動体と接触させて該流動体
で上記形成される小滴を被覆することにより、被
覆小滴を作成する。
この被覆小滴の作成は、例えば添付図に示した
ような装置を用いて行ない得る。
まず、不安定な機能性物質を含有する流動体
と、ポリアニオン多糖類又はその塩もしくはそれ
らの混合物を主材とする流動体をそれぞれ調製
し、前者の流動体2を添付図に示した2重の円筒
ノズルを具えた円筒体の円筒のノズル4へ供給し
て押出すと共に、後者の流動体1を外筒のノズル
3へ供給して押出すことにより、内筒のノズル4
の出口で形成される流動体2の小滴が外筒のノズ
ル3の出口からの流動体1により被覆されるよう
になる。
上記小滴の被覆に当つては、上記円筒体の内筒
ノズルと外筒ノズルの径及びこれら各ノズルへの
各流動体の供給流量をコントロールすることによ
り被覆を連続方式で行なうことができる。
ついで、本発明では上述のようにして作成した
被覆小滴を可溶性キチン誘導体の溶液と接触させ
る。この接触は、上記被覆小滴を上記溶液中へ緩
徐に撹拌しながら滴下するようにして行なうとよ
い。
上記接触により、小滴の被覆層中のポリアニオ
ン多糖類と溶液中のキトサンとの間に荷電による
架橋反応、すなわち架橋結合が起つてゲル状物質
を生成し、カプセル体としての皮膜を形成するよ
うになる。そして、この際一旦ゲル皮膜が形成さ
れると該皮膜に内包されて芯部を構成する溶液の
ゲル化は実質上全く起きないので所望のカプセル
体が得られる。なお、このような現象は、上記に
よりゲル皮膜が形成されると該皮膜に内包された
溶液(すなわち芯液)中のポリアニオン重合体お
よびキトサン分子がもはや上記皮膜を透過できな
くなつて上記反応が芯液中で進行しなくなること
に因るものと考えられる。
本発明では、カプセル体の芯部を構成する流動
体として用いる溶液の調製に当つてはポリアニオ
ン多糖類またはその塩もしくはそれらの混合物を
0.3〜1.0重量%含む水溶液とすることが適当であ
り、特にポリアニオン多糖類としてカルボキシメ
チルセルロースを用いるのがゲル皮膜形成上好ま
しい。
また、上記水溶液を接触させるキトサン溶液
は、酢酸のような弱酸に0.5〜1.0重量%の濃度に
溶解したものが適当である。
発明の作用効果
上述したとおり、本発明では、カプセル体のゲ
ル皮膜を有機溶剤などを使用することなく、極め
て温和な条件、すなわち、生物学的に温和な条件
下で短時間に形成し得るので、不安定な生物学的
物質や機能性物質および更にはカプセル体の使用
目的に応じその他の種々の添加物を、カプセル体
の芯部を構成する前記流動体に添加して分散させ
ることができるので、種々の有用物質を芯液に含
有させたカプセル体を提供することが可能とな
る。
又、本発明は、ゲル皮膜の形成によるカプセル
化を1段階で行ない得るので、例えば特開昭57−
197031号にみられるポリアニオンとポリカチオン
間の塩架橋を利用した公知のカプセル化法に比し
製造上有利であるといえる。
更に、本発明ではカプセル体のゲル皮膜の形成
条件をコントロールすることにより、該皮膜の膜
透過性を変化させることも可能であるので、カプ
セル体の皮膜に分画機能を付与することも可能と
なる。
叙上のとおり、本発明によると、入手な容易の
原材料を用いて簡易な製造手段でしかも短時間で
不安定な機能性物質のカプセル化に適した、かつ
広範囲な用途に供し得るカプセル体を提供し得る
利点がある。
以下に実施例を示して本発明を更に具体的に説
明する。
実施例
不安定な機能性物質としてモノクロナール抗ヒ
トラクトフエリン抗体産性ハイブリドーマを用い
た。これを4×104cells/mlになるようにDMEM
培地(10%血清を含む)に分散し、これを(A
液)とする。一方ポリアニオン多糖類としてカル
ボキシメチルセルロースを用いそれの0.5重量%
水溶液(B液)を調製した。
上述のA液を添付図に示した2重の円筒ノズル
の内筒ノズル4に供給すると共にB液を外筒ノズ
ル3に供給してそれらのノズルの出口においてA
液の小滴を形成すると共に該小滴をB液で被覆し
た。
参考として、上記小滴の形成と被覆に用いた2
重の円筒ノズルの内筒ノズルおよび外筒ノズルの
径と上記A液およびB液のこれらノズルへの供給
流量を下記表に示す。
Industrial Application Field The present invention relates to a capsule body containing an unstable functional substance and a method for producing the same, and more specifically, a capsule body containing an unstable functional substance, and more specifically, a capsule body containing an unstable functional substance, and more specifically, a capsule body that utilizes a gel film formed by contacting a polyanionic polysaccharide or a salt thereof with a soluble chitin derivative. The present invention relates to the capsule body and its manufacturing method. Conventional technology Conventionally, as a method for manufacturing capsule bodies, a mixture of a fluid (core liquid) constituting the core of the capsule body and a polyvalent metal salt such as a calcium salt is added to alginate or low methoxyl pectin or a mixture thereof. A method of forming a gel film by contacting with a solution of a mixture (Japanese Patent Publication No. 48-16183), an aqueous solution containing a de-N-acetylated product of carboxylmethyl chitin or a carboxylmethyl chitin salt,
A method for producing capsule bodies by dropping, stirring, and dispersing an organic acid in an aqueous anhydride solution such as a mixture of acetic anhydride and acetic acid (Japanese Patent Application Laid-open No. 55-90503)
etc. are known. However, these known methods have the following drawbacks in encapsulating unstable functional substances, such as animal cells that produce useful substances. The ionic strength of the liquid (core liquid) that makes up the core of the capsule body is too high. A rapid change in the hydrogen ion concentration of the core fluid is observed during the capsule formation process.
There is a risk that the substance involved in capsule membrane formation contained in the core liquid and the unstable functional substance may directly interact, causing the functionality to disappear or be inhibited.
Due to the high viscosity of the liquid inside the capsule, it is difficult to uniformly spread the substance inside the capsule. Problems to be Solved by the Invention In view of the above-mentioned problems with capsules produced by conventionally known methods, the inventors have studied capsules particularly suitable for unstable functional substances, and have found the following: When a solution of a chitin derivative such as chitosan is brought into contact with a solution of a polyanionic polysaccharide or its salt, an excellent gel film is formed even under biologically mild conditions, and in this case, it is possible to form an excellent gel film even under biologically mild conditions. When a droplet of a solution containing a stable functional substance coated with a solution of the polyanionic polysaccharide or its salt is encapsulated by contacting with a solution of the chitin derivative, it participates in capsule formation with the functional substance. The present invention was developed based on the knowledge that the interaction between the capsule and the substance used in the capsule becomes extremely weak, and the viscosity of the core liquid within the capsule also becomes extremely low. Therefore, an object of the present invention is to provide a capsule body that can encapsulate an unstable functional substance without impairing the functional properties of the substance, and a method for producing the same. The present invention will be explained in detail below. Structure of the Invention The capsule body according to the present invention is characterized by coating small droplets of a fluid containing an unstable functional substance with a fluid mainly composed of a polyanionic polysaccharide, a salt thereof, or a mixture thereof. The coated droplet is encapsulated as a core in a gel film formed by contacting the droplet with a solution of a soluble chitin derivative. Furthermore, the method for manufacturing the capsule body according to the present invention is characterized in that a fluid containing an unstable functional substance is extruded from an inner cylindrical nozzle of a double cylindrical nozzle to form small droplets, and the droplets are formed into small droplets. In the formation process, a fluid mainly composed of a polyanionic polysaccharide, a salt thereof, or a mixture thereof is extruded from an outer cylinder nozzle disposed parallel to the outside of the inner cylinder nozzle. coating the droplets that form;
The resulting coated droplets are then contacted with a solution of a soluble chitin derivative to form a gel film. The polyanionic polysaccharide or salt thereof used in the present invention is a polysaccharide or a salt thereof that forms a polyanionic polymer in an aqueous solution, and examples thereof include low methoxyl pectin, carrageenan, carboxymethyl cellulose, sodium alginate, chondroitin sulfate, and heparin. . These polysaccharides can be used alone or as a mixture. In addition, the soluble chitin derivative used in the present invention is
Chitin, which is originally an insoluble substance, is chemically treated to increase its reaction activity, and chitosan, which is obtained by deacetylating chitin, is a typical example. Incidentally, chitin is N contained in the carapace of crabs, krill, insects, etc., the cell walls of microorganisms, and mushrooms.
- It is a linear homopolysaccharide in which acetyl-D-glucosamine is β (1 → 4) linked, and is abundantly produced in nature, but it is an unused natural resource that cannot be used as it is because of its inactivity. It can be said. However, chitin derivatives such as chitosan obtained by deacetylating chitin become soluble in dilute acids and have reactive activity. That is, chitosan has a structural unit represented by the following general formula (), It is positively charged due to the amino group in the formula, has chitosan molecules as a polycationic polymer, and exhibits reactive activity. Means for Solving the Problems In the present invention, a fluid containing an unstable functional substance is formed into droplets, and during the formation process, the polyanionic polysaccharide, its salt, or a mixture thereof is used as the main material. A coated droplet is created by contacting the formed droplet with a fluid that coats the formed droplet. The production of the coated droplets may be carried out, for example, using an apparatus such as that shown in the accompanying figures. First, a fluid containing an unstable functional substance and a fluid mainly composed of a polyanionic polysaccharide, its salt, or a mixture thereof were prepared, and the former fluid 2 was divided into two fluids as shown in the attached diagram. By supplying the latter fluid 1 to the cylindrical nozzle 4 of the cylindrical body having a cylindrical nozzle and extruding it, and supplying the latter fluid 1 to the nozzle 3 of the outer cylinder and extruding it, the inner cylinder nozzle 4
The droplets of fluid 2 formed at the outlet of the nozzle 3 of the barrel become covered by the fluid 1 from the outlet of the nozzle 3 of the barrel. Coating with the droplets can be carried out in a continuous manner by controlling the diameters of the inner and outer nozzles of the cylindrical body and the flow rates of the fluids supplied to these nozzles. In the present invention, the coated droplets prepared as described above are then contacted with a solution of a soluble chitin derivative. This contact is preferably carried out by dropping the coated droplet into the solution with slow stirring. Due to the above contact, a charged crosslinking reaction, that is, a crosslinking bond, occurs between the polyanionic polysaccharide in the coating layer of the droplet and the chitosan in the solution, producing a gel-like substance and forming a film as a capsule body. become. At this time, once the gel film is formed, the solution contained in the film and constituting the core does not gel substantially at all, so that the desired capsule body can be obtained. This phenomenon occurs because once a gel film is formed as described above, the polyanionic polymer and chitosan molecules in the solution (i.e. core liquid) contained in the film can no longer pass through the film, and the above reaction is delayed. This is thought to be due to the fact that it stops progressing in the core liquid. In the present invention, a polyanionic polysaccharide, a salt thereof, or a mixture thereof is used in preparing the solution used as the fluid constituting the core of the capsule body.
It is appropriate to prepare an aqueous solution containing 0.3 to 1.0% by weight, and it is particularly preferable to use carboxymethylcellulose as the polyanionic polysaccharide from the viewpoint of forming a gel film. The chitosan solution with which the above aqueous solution is brought into contact is suitably one dissolved in a weak acid such as acetic acid to a concentration of 0.5 to 1.0% by weight. Effects of the Invention As described above, in the present invention, the gel film of the capsule body can be formed in a short time under extremely mild conditions, that is, biologically mild conditions, without using organic solvents. , unstable biological substances, functional substances, and various other additives depending on the intended use of the capsule can be added to and dispersed in the fluid constituting the core of the capsule. Therefore, it is possible to provide a capsule body containing various useful substances in the core liquid. In addition, the present invention enables encapsulation by forming a gel film in one step.
It can be said that this method is advantageous in terms of production compared to the known encapsulation method that utilizes salt crosslinking between a polyanion and a polycation as seen in No. 197031. Furthermore, in the present invention, by controlling the formation conditions of the gel film of the capsule body, it is possible to change the membrane permeability of the gel film, so it is also possible to impart a fractionation function to the film of the capsule body. Become. As described above, the present invention provides a capsule body that is suitable for encapsulating unstable functional substances in a short period of time using easily available raw materials, and can be produced easily and in a short time, and that can be used for a wide range of applications. There are benefits it can offer. EXAMPLES The present invention will be explained in more detail with reference to Examples below. Example A monoclonal anti-human lactoferrin antibody-producing hybridoma was used as an unstable functional substance. Add this to DMEM to 4×10 4 cells/ml.
Disperse in a medium (containing 10% serum) and add it to (A
liquid). Meanwhile, using carboxymethylcellulose as polyanionic polysaccharide, 0.5% by weight of it
An aqueous solution (solution B) was prepared. The above-mentioned liquid A is supplied to the inner cylinder nozzle 4 of the double cylindrical nozzle shown in the attached figure, and liquid B is supplied to the outer cylinder nozzle 3, and the liquid A is supplied at the outlet of these nozzles.
A droplet of liquid was formed and the droplet was coated with liquid B. For reference, 2 used for forming and coating the droplets above.
The diameters of the inner and outer nozzles of the heavy cylindrical nozzle and the flow rates of the liquids A and B supplied to these nozzles are shown in the table below.
【表】
ついで、このようにして形成した被覆小滴を
0.7重量%のキトサンの溶液中に滴下してカプセ
ル体を作成した。
このようにして得られたカプセル体の芯液中の
抗体蛋白産生ハイブリドーマはその生存が確認さ
れ、さらに4日後にその増殖を確認できた。カプ
セル体は直径3〜4mmを有し、透明であつて、走
査型電子顕微鏡による観察ではカプセルの皮膜の
厚さは2〜3μmであつた。
また、このカプセル体は機械的強度も強く、カ
プセル体芯液中のカルボキシメチルセルロースの
濃度が0.1〜0.2重量%に低下していた。[Table] Next, the coated droplets formed in this way were
A capsule body was prepared by dropping it into a 0.7% by weight chitosan solution. The survival of the antibody protein-producing hybridoma in the core fluid of the capsule body thus obtained was confirmed, and its proliferation was further confirmed 4 days later. The capsule body had a diameter of 3 to 4 mm and was transparent, and the thickness of the capsule film was 2 to 3 μm when observed using a scanning electron microscope. In addition, this capsule body also had high mechanical strength, and the concentration of carboxymethyl cellulose in the core liquid of the capsule body was reduced to 0.1 to 0.2% by weight.
添付図は、本発明において、不安定な機能性物
質を含有する流動体の小滴を形成し、かつ該小滴
をポリアニオン多糖類を主材とする流動体で被覆
するために用いる装置を例示したものである。
図において、1……ポリアニオン多糖類を主材
とする流動体、2……不安定な機能性物質を含有
する流動体、3……外筒ノズル、4……内筒ノズ
ル。
The attached figure illustrates the apparatus used in the present invention to form droplets of a fluid containing labile functional substances and to coat the droplets with a fluid based on a polyanionic polysaccharide. This is what I did. In the figure, 1...Fluid mainly composed of polyanionic polysaccharide, 2...Fluid containing unstable functional substance, 3...Outer tube nozzle, 4...Inner tube nozzle.
Claims (1)
をポリアニオン多糖類又はその塩もしくはそれら
の混合物を主材とする流動体で被覆した被覆小滴
と可溶性キチン誘導体の溶液との接触により形成
されたゲル皮膜で、上気被覆小滴を芯部として内
包して成る不安定な機能性物質を内包したカプセ
ル体。 2 不安定な機能性物質を含有する流動体を2重
円筒体ノズルの内筒ノズルから押出して小滴に形
成すると共に、該小滴の形成過程において、ポリ
アニオン多糖類又はその塩もしくはそれらの混合
物を主材とする流動体を上記内筒ノズルの外側に
平行的に配設された外筒ノズルから押出すことに
より、該流動体で上記形成される小滴を被覆し、
ついで得られた被覆小滴を可溶性キチン誘導体の
溶液と接触させてゲル皮膜を形成することを特徴
とする不安定な機能性物質を内包したカプセル体
の製造法。[Scope of Claims] 1 Coated droplets of a fluid containing an unstable functional substance coated with a fluid containing a polyanionic polysaccharide, a salt thereof, or a mixture thereof, and a coated droplet of a soluble chitin derivative. A capsule body containing an unstable functional substance, which is made of a gel film formed by contact with a solution and has a core of air-covered droplets. 2 A fluid containing an unstable functional substance is extruded from the inner cylindrical nozzle of a double cylindrical nozzle to form droplets, and in the process of forming the droplets, a polyanionic polysaccharide or a salt thereof or a mixture thereof is extruded. Covering the formed droplets with the fluid by extruding a fluid mainly composed of from an outer cylinder nozzle disposed parallel to the outside of the inner cylinder nozzle,
A method for producing a capsule body containing an unstable functional substance, characterized in that the coated droplets obtained are then brought into contact with a solution of a soluble chitin derivative to form a gel film.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59132729A JPS6111139A (en) | 1984-06-27 | 1984-06-27 | Capsule body encapsulating instable functional substance and its manufacture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59132729A JPS6111139A (en) | 1984-06-27 | 1984-06-27 | Capsule body encapsulating instable functional substance and its manufacture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6111139A JPS6111139A (en) | 1986-01-18 |
| JPH0456660B2 true JPH0456660B2 (en) | 1992-09-09 |
Family
ID=15088222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59132729A Granted JPS6111139A (en) | 1984-06-27 | 1984-06-27 | Capsule body encapsulating instable functional substance and its manufacture |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6111139A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62166891A (en) * | 1986-01-20 | 1987-07-23 | Snow Brand Milk Prod Co Ltd | Production of useful substance by cell cultivation |
| JP2594367B2 (en) * | 1988-04-18 | 1997-03-26 | 新田ゼラチン株式会社 | Mass production of animal cells and production of support substrate for culture |
| US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| JP2001000509A (en) * | 1999-06-25 | 2001-01-09 | Kao Corp | Method for producing capsule particles |
| CN109701442B (en) * | 2017-10-25 | 2021-11-16 | 中国石油化工股份有限公司 | Dropping ball device for dropping ball forming and oil ammonia column forming device |
| CN109701443B (en) * | 2017-10-25 | 2022-05-17 | 中国石油化工股份有限公司 | Method for forming dropping ball |
| CN111068579B (en) * | 2018-10-22 | 2022-07-12 | 中国石油化工股份有限公司 | Method of drop ball forming |
-
1984
- 1984-06-27 JP JP59132729A patent/JPS6111139A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6111139A (en) | 1986-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5089272A (en) | Process for producing capsules having a permeability-controllable membrane | |
| US6165503A (en) | High strength capsules, process of preparing and using the same | |
| Gåserød et al. | Microcapsules of alginate–chitosan. II. A study of capsule stability and permeability | |
| CA2194976C (en) | Wound healing agent | |
| Polk et al. | Controlled release of albumin from chitosan-alginate microcapsules | |
| JP6483740B2 (en) | Polymer shell | |
| WO1993012875A1 (en) | Method and apparatus for producing uniform polymeric spheres | |
| EP1063970A1 (en) | Slow release microcapsules | |
| CN102631680B (en) | Method of regulating microsphere drug-load rate by treating calcium alginate microspheres with sodium chloride solution | |
| JPH0456660B2 (en) | ||
| CN111407722B (en) | A kind of silver nanoparticle composite hydrogel, its preparation method and application | |
| CN101724163A (en) | Composite microsphere of chitosan derivative, preparing method and applications thereof | |
| EP2552405A2 (en) | Method for producing a drug delivery system on the basis of polyelectrolyte complexes | |
| JPH0453583B2 (en) | ||
| CN110698698A (en) | A kind of preparation method of chitosan hydrogel | |
| KR910003557B1 (en) | Process for preparing liquid prolonged release pharmaceutical formulations | |
| Quigley et al. | Use of deacetylated gellan gum (Gelrite) for the production of sulphamethizole containing beads | |
| CS268652B2 (en) | Method of microporous bodie production that occlude one or more active agents | |
| CN106389386A (en) | Biocompatible cross-linking micro-nano material for drug encapsulation and sustained release and preparation technology of biocompatible cross-linking micro-nano material for drug encapsulation and sustained release | |
| DE102011055861B4 (en) | Process for the preparation of monodisperse pectin microgels using a microfluidic system | |
| JPS61125433A (en) | Method for manufacturing microcapsules | |
| JPH0461882B2 (en) | ||
| JPH058049B2 (en) | ||
| Zhang et al. | Modulation of electroosmotic flow in open tubular capillary electrochromatography by chitosan-assisted titanium oxide nanoparticles liquid phase deposition | |
| JPH01245848A (en) | Production of capsule body with film of controllable permeability |